Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
Study shows how arthritis affects people's working lives

Study shows how arthritis affects people's working lives

Combination treatment does not slow radiographic spinal progression in radiographic axSpA patients

Combination treatment does not slow radiographic spinal progression in radiographic axSpA patients

Study estimates the quality of care for patients with long-term health conditions

Study estimates the quality of care for patients with long-term health conditions

New data analysis approach could help uncover the genetic basis of many diseases

New data analysis approach could help uncover the genetic basis of many diseases

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Exploring the effectiveness of various treatments in people with axial spondyloarthritis

Exploring the effectiveness of various treatments in people with axial spondyloarthritis

After SARS-CoV-2 infection, anti-chemokine antibodies correlate with better outcomes

After SARS-CoV-2 infection, anti-chemokine antibodies correlate with better outcomes

Study explores COVID-19 vaccine effectiveness in ankylosing spondylitis patients

Study explores COVID-19 vaccine effectiveness in ankylosing spondylitis patients

As covid slogs on, seniors find fortitude waning and malaise growing

As covid slogs on, seniors find fortitude waning and malaise growing

Are our bowel habits written in our DNA?

Are our bowel habits written in our DNA?

Innovative artificial neural network can accurately detect radiographic sacroiliitis

Innovative artificial neural network can accurately detect radiographic sacroiliitis

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Study examines the role of programmed cell death ligands in skin immune responses

Study examines the role of programmed cell death ligands in skin immune responses

Passive smoking and air pollution associated with arthritis risk, poor response to RA treatment

Passive smoking and air pollution associated with arthritis risk, poor response to RA treatment

Study explores COVID-19 outcomes in people with RA

Study explores COVID-19 outcomes in people with RA

Study discovers harmful inflammatory protein in patients with symptomatic tuberculosis

Study discovers harmful inflammatory protein in patients with symptomatic tuberculosis

Defective epithelial barrier responsible for up to two billion chronic diseases

Defective epithelial barrier responsible for up to two billion chronic diseases